PATIENT ENGAGEMENT

 

IMPORTANT COUNSELING POINTS

Red Cross Icon


Inform patients that they may experience adverse reactions after receiving SHINGRIX. In clinical trials, the most common adverse reactions observed were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.1

Because each patient’s clinical situation is unique, GSK has no specific recommendations on adverse reaction management. GSK recommends healthcare professionals use their clinical judgment. Specific management of adverse reactions was not studied in the clinical trials of SHINGRIX.

The Immunization Action Coalition (IAC) recommends if localized reaction occurs, such as soreness, redness, itching, or swelling at the injection site, to apply a cold compress to the injection site. Consider giving an analgesic (pain reliever) or antipruritic (anti-itch) medication. These are general recommendations from IAC and have not been evaluated with SHINGRIX.2

2-Dose Series Injection Icon


Explain to patients that the efficacy of SHINGRIX was only studied in patients who received 2 doses of the vaccine. In order for your patients to get results similar to those from the studies, they need to receive both doses.1

Calendar Icon To ensure series completion, encourage your patients to schedule their second dose for anytime between 2 and 6 months after their first dose.

TOPICS TO DISCUSS WITH YOUR PATIENTS

Inform patients of the potential benefits and risks of immunization with SHINGRIX.

Shingles Disease Risk

99% of people ≥50 years of age are at risk for developing shingles, and 1 out of 3 people will get shingles. The risk increases with age, especially after age 50.3,4

Indication

SHINGRIX is indicated for prevention of shingles in adults aged 50 years and older.1

Efficacy

SHINGRIX delivers >90% efficacy against shingles in patients ≥50 years of age.1

Safety

In clinical trials with SHINGRIX, the majority of reactions were mild to moderate (grade 1 or 2) and transient (median duration of 2 to 3 days). Some grade 3 reactions were observed.1
Please see the 'Safety Profile' section for more information.


Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

References: 1. Prescribing Information for SHINGRIX. 2. Immunization Action Coalition. Medical Management of Vaccine Reactions in Adult Patients. www.immunize.org/catg.d/p3082.pdf. Accessed November 1, 2017. 3. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. 4. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30.

All trademarks are the property of their respective owners.

1004182R0 April 2018